December 27, 2023 – Acute Respiratory Misery Syndrome (ARDS) is a life-threatening lung illness with causes together with extreme pneumonia and sepsis, resulting in excessive mortality charges amongst hospitalized sufferers. There are presently no authorised therapies or remedies for ARDS. Thermo Fisher Scientific has been chosen by the Biomedical Superior Analysis and Growth Authority (BARDA) to conduct the primary BARDA-supported Part II medical platform trial to analyze therapeutic choices for the therapy of ARDS.

The first aim of the BARDA-funded, hypothesis-generating examine is to gather complete medical and biomarker knowledge on the ARDS affected person inhabitants to raised inform future medical trials and contribute to the event of focused therapies for ARDS.

Be taught extra